Home » Aggrastat Case Series

Aggrastat Case Series

Interventional Cardiologists in the U.S. present a case series on the contemporary use of glycoprotein IIb/IIIa inhibitors (GPIs). 

The series is based on cases where patient treatment included Aggrastat (tirofiban hydrochloride) injection and is intended to be an educational resource for fellows and those who may not be familiar with the use of GPIs. 

These cases and testimonials are based on the experiences of a few people. Not all cases are identical. You are not likely to have similar results. 

Important Safety Information about the use of Aggrastat is provided below. 

Clinical studies performance with Aggrastat are provided in the full Prescribing Information

Meet our Presenters

We reached out to Interventional Cardiologists in the U.S. who had experience using Aggrastat and asked them to presented 3 cases in which they have used Aggrastat in their practice. All presenters were provided financial support for the creation of these videos by Medicure Inc. All cases presented are real cases. 

Click the image below to see the 3 unique cases presented by each of the physician presenters, or scroll down to view all our entire case series. 

Cases Series

Below you will find all cases that are currently available to view. 

ACS with no DAPT Pre-Procedure

Intraprocedural Thrombus Formation

Short Infusion Administration in Patient with NSTE-ACS

Clot Develops Intracoronary During PCI

Patient Not Pre-Treated with Oral Anti-Platelet Therapy

Patient Presenting to ED with NSTEMI

Patient Admitted for NSTEMI with Suspected CTO

Patient Not Pre-Loaded with DAPT prior to PCI

Slow Reflow following PCI

Patient Requiring Urgent Cardiac Catheterization

Patient Not Pre-Loaded with DAPT prior to PCI

About Aggrastat

Aggrastat (tirofiban hydrochloride) is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). Aggrastat:
  • Offers protection during the delayed onset of the oral P2Y12 agents*
  • Has a rapid onset, achieving >90% platelet aggregation inhibition within 10 minutes1
  • Is reversible: platelets return to baseline function within 4 to 8 hours of discontinuation of infusion
  • Has no contraindication for patients on hemodialysis
  • Has no drug interactions with oral P2Y12 inhibitors*
* Concomitant use of fibrinolytic, anticoagulants and antiplatelet drugs increases the risk of bleeding.
1 Mardikar HM et al. Am Heart J. 2007;154(344):e1-5
Aggrastat Pharmacy Product
Important Safety Information

Indication:

Aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

Contraindications:

  • Known hypersensitivity to any component of Aggrastat®.
  • History of thrombocytopenia with prior exposure to Aggrastat®.
  • Active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within the previous month.

Warnings and Precautions:

  • Aggrastat® can cause serious bleeding. Most bleeding associated with Aggrastat® occurs at the arterial access site for cardiac catheterization. Minimize the use of traumatic or potentially traumatic procedures such as arterial and venous punctures, intramuscular injections, nasotracheal intubation, etc. Concomitant use of fibrinolytics, anticoagulants and antiplatelet drugs increases the risk of bleeding. If bleeding cannot be controlled, discontinue Aggrastat®.
  • Thrombocytopenia: discontinue Aggrastat® and heparin.

Adverse Reactions:

  • Bleeding is the most commonly reported adverse reaction.

For additional information, refer to the full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.FDA.gov/medwatch
or call 1-800-FDA-1088.

x

Subscribe